Therapeutic drug monitoring (TDM) has emerged as a useful tool for optimising the use of
biologics, and in particular anti-tumour necrosis factor (anti-TNF) therapy, in inflammatory …

Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimization in
inflammatory bowel diseases to maximize benefit and to reach more stringent, objective end …

Ulcerative colitis (UC) and Crohn's disease (CD) are part of Inflammatory Bowel Diseases
(IBD) and have pathophysiological processes such as bowel necrosis and enteric neurons …

Background & Aims Proactive therapeutic drug monitoring (TDM) has been proposed to
improve outcomes in patients with inflammatory bowel disease (IBD) treated with tumor …

The management of moderate to severe ulcerative colitis has undergone significant
changes over the past 15 years due to the regulatory approval of several new drugs. In …

Biologic drugs have greatly improved treatment outcomes of inflammatory joint diseases, but
a substantial proportion of patients either do not respond to treatment or lose response over …

Anti-TNF therapy has been successfully used as first-line biologic treatment for moderate-to-
severe inflammatory bowel disease (IBD), in both 'step-up'and 'top-down'approaches, and …

There is great heterogeneity among inflammatory bowel disease (IBD) patients in terms of
pathogenesis, clinical manifestation, response to treatment, and prognosis, which requires …

Introduction Preliminary data indicates that proactive therapeutic drug monitoring (TDM) is
associated with better outcomes compared with empiric dose escalation and/or reactive …

A cure for Crohn's disease (CD), a chronic inflammatory disease of the gastrointestinal tract
of unknown etiology, is not available, so patients require lifelong management to keep …